Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure

NCT00011375 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT00011375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00011375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2001
Completion date
April 30, 2004
Enrollment
52
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis